Conference Call and Webcast Access
AMAG Pharmaceuticals, Inc. will host a conference call and webcast today at 8:00 a.m. E.T. to discuss the data from this study. To access the conference call via telephone, dial 877-412-6083 from the United States or 702-495-1202 for international access. To access a telephone replay of the call, dial 855-859-2056 from the United States or 404-537-3406 for international access. The telephone replay will be available at approximately 11:00 a.m. E.T. July 18, 2012 through midnight July 22, 2012. The pass code for the live call and the telephone replay is 96188567.
The call will be webcast live and archived through the Investors section of the company’s website at
on July 18, 2012 at 8:00 a.m. E.T.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that manufactures and markets
® in the United States. For additional company information, please visit
AMAG Pharmaceuticals and
are registered trademarks of AMAG Pharmaceuticals, Inc.
In the United States, Feraheme® (ferumoxytol) Injection for Intravenous (IV) use is indicated for the treatment of iron deficiency anemia in adult chronic kidney disease (CKD) patients.
received marketing approval from the U.S. Food and Drug Administration on June 30, 2009 and was commercially launched by AMAG in the U.S. shortly thereafter. Ferumoxytol
received marketing approval in Canada in December 2011 and in the European Union in June 2012. For additional product information, please visit
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to: the preliminary nature of the data being reported in this press release, the fact that no new
safety signals were identified, our expectation to seek approval for
for treatment of the broader population of patients with iron deficiency anemia and a history of an unsatisfactory response to oral iron therapy, our belief that
could be a valuable therapeutic alternative to currently approved IV irons for the treatment of their iron deficiency anemia, and our intent to submit a supplemental new drug application for the broad IDA indication to the U.S. Food and Drug Administration by year-end 2012.
Such risks and uncertainties include: (1) uncertainties regarding our and Takeda's ability to successfully compete in the intravenous iron replacement market both in the U.S. and outside the U.S., (2) uncertainties regarding our ability to successfully and timely complete our clinical development programs and obtain regulatory approval for
in the broader IDA indication both in the U.S. and in territories outside of the U.S., including the European Union, (3) the fact that significant safety or drug interaction problems could arise with respect to
, (4) the risk that final data from the clinical trial described herein could differ materially from or be subject to differing interpretations by regulatory authorities than set forth in this press release, (5) uncertainties regarding our ability to manufacture
, (6) uncertainties relating to our patents and proprietary rights, and (7) other risks identified in our Securities and Exchange Commission filings, including our Quarterly Report on Form 10-Q for the three months ended March 31, 2012. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.
We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.